Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer

References

• Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2015. CA: a cancer journal for clinicians, 2015. 65(1): 5–29; PMID:25559415
   PubMed Web of Science ®Google Scholar
• Mariotto, AB, Yabroff, KR, Shao, Y, Feuer, EJ, Brown, ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011. 103(2): 117–28; PMID:21228314; http://dx.doi.org/10.1093/jnci/djq495
   PubMed Web of Science ®Google Scholar
• Ewald, B, Sampath, D, Plunkett, W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res, 2008. 68(19):7947–55; PMID:18829552; http://dx.doi.org/10.1158/0008-5472.CAN-08-0971
   PubMed Web of Science ®Google Scholar
• Liu, X. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Transl Oncol 2015. 8(3): p. 185–95; PMID:26055176; http://dx.doi.org/10.1016/j.tranon.2015.03.010
   PubMed Web of Science ®Google Scholar
• Strebhardt, K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9(8):643–60; PMID:20671765; http://dx.doi.org/10.1038/nrd3184
   PubMed Web of Science ®Google Scholar
• Song, B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, Ratliff TL, Hazbun T, Chiorean EG, Liu X. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Molecular cancer therapeutics 2013; 12(1):58–68; PMID:23188630; http://dx.doi.org/10.1158/1535-7163.MCT-12-0632
   PubMed Web of Science ®Google Scholar
• Weichert, W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P, Bahra M, Denkert C, Dietel M, Kristiansen G. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatol : Off J Int Asso Pancreatol 2005; 5(2–3):259–65; PMID:15855824; http://dx.doi.org/10.1159/000085280
   PubMed Web of Science ®Google Scholar
• Russo, MA, Kang, KS, Di, A. Cristofano, The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations. Thyroid 2013; 23(10):1284–93; PMID:23509868; http://dx.doi.org/10.1089/thy.2013.0037
   PubMedGoogle Scholar
• Song, B, Liu, XS, Liu, X. Polo-like kinase 1 (Plk1): an Unexpected Player in DNA Replication. Cell Div 2012; 7:3; PMID:22309699; http://dx.doi.org/10.1186/1747-1028-7-3
   PubMed Web of Science ®Google Scholar
• Liu, XS, Song, B, Liu, X. The substrates of Plk1, beyond the functions in mitosis. Protein Cell 2010; 1(11):999–1010; PMID:21153517; http://dx.doi.org/10.1007/s13238-010-0131-x
   PubMed Web of Science ®Google Scholar
• Ouyang, H, Mou LJ, Luk C, Liu N, Karaskova J, Squire J, Tsao MS. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 2000; 157(5):1623–31; PMID:11073822; http://dx.doi.org/10.1016/S0002-9440(10)64800-6
   PubMed Web of Science ®Google Scholar
• Liu, X, Lei, M, Erikson, RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26(6):2093–108; PMID:16507989; http://dx.doi.org/10.1128/MCB.26.6.2093-2108.2006
   PubMed Web of Science ®Google Scholar
• Liu, X, Erikson, RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 2003; 100(10):5789–94; PMID:12732729; http://dx.doi.org/10.1073/pnas.1031523100
   PubMed Web of Science ®Google Scholar
• Olmos, D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17(10):3420–30; PMID:21459796; http://dx.doi.org/10.1158/1078-0432.CCR-10-2946
   PubMed Web of Science ®Google Scholar
• Chou, TC, Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27–55; PMID: 6382953; http://dx.doi.org/10.1016/0065-2571(84)90007-4
   PubMedGoogle Scholar
• Song, B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, Ratliff TL, Hazbun T, Chiorean EG, Liu X. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 2013; 12(1):58–68; PMID:23188630; http://dx.doi.org/10.1158/1535-7163.MCT-12-0632
   PubMed Web of Science ®Google Scholar
• Wu, ZQ, Liu, X. Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing. Proc Natl Acad Sci U S A 2008; 105(6):1919–24; PMID:18250300; http://dx.doi.org/10.1073/pnas.0712063105
   PubMed Web of Science ®Google Scholar
• Yata, K, Lloyd J, Maslen S, Bleuyard JY, Skehel M, Smerdon SJ, Esashi F. Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. Mol Cell 2012; 45(3):371–83; PMID:22325354; http://dx.doi.org/10.1016/j.molcel.2011.12.028
   PubMed Web of Science ®Google Scholar
• Li, H, Wang, Y, Liu, X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem 2008; 283(10):6209–21; PMID:18171681; http://dx.doi.org/10.1074/jbc.M709007200
   PubMed Web of Science ®Google Scholar
• Keppner, S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle 2010; 9(4):761–73; PMID:20139717; http://dx.doi.org/10.4161/cc.9.4.10644
   PubMed Web of Science ®Google Scholar
• Li, J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, Ratliff TL, Konieczny SF, Liu X. Co-targeting Polo-like kinase 1(Plk1) and the Wnt/beta-catenin signaling pathway in castration-resistant prostate cancer. Mol Cell Biol 2015; 35:4185–98; PMID:26438599
   PubMed Web of Science ®Google Scholar
• Zhang, Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T, Liu X. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res 2014; 74(22):6635–47; PMID:25252916; http://dx.doi.org/10.1158/0008-5472.CAN-14-1916
   PubMed Web of Science ®Google Scholar
• Zhang, Z, Chen L, Wang H, Ahmad N, Liu X. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer. Cell Cycle 2015; 14(13):2142–8; PMID:25927139; http://dx.doi.org/10.1080/15384101.2015.1041689
   PubMed Web of Science ®Google Scholar
• Li, Z, Li J, Bi P, Lu Y, Burcham G, Elzey BD, Ratliff T, Konieczny SF, Ahmad N, Kuang S, et al. Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State. Mol Cell Biol 2014; 34:3642–61; PMID:2504783; http://dx.doi.org/10.1128/MCB.00814-14
   PubMed Web of Science ®Google Scholar
• Li, Z, Lu Y, Ahmad N, Strebhardt K, Liu X. Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1). Cell Cycle 2015; 14:3030–9; PMID:26709750; http://dx.doi.org/10.1080/15384101.2015.1120924
   PubMed Web of Science ®Google Scholar
• Shao, C, Ahmad N, Hodges K, Kuang S, Ratliff T, Liu X. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. J Biol Chem 2015; 290(4):2024–33; PMID:25505174; http://dx.doi.org/10.1074/jbc.M114.596817
   PubMed Web of Science ®Google Scholar